Radiopharmaceuticals are rapidly evolving, and RDC (Radionuclide Drug Conjugate), as a member of them, are receiving lots of attention. An in-depth understanding of binding interactions between targeted molecules and ligand is crucial to elucidating binding mechanisms and stability during the RDC development.
Rdcthera have set up an excellent RDC analysis platform and standard procedures to provide cost-effective and customized complement radioligand binding analysis service for global clients.
The targeting molecule in RDC, working as a vector, is one kind of ligand, that enables identification and binding with the specific receptors expressed on the targeted cell when RDC is infused into the bloodstream. The radioactive isotope in the RDC is effectively used in diagnostic imaging and cancer treatment.
Binding affinity refers to the strength of interaction between a receptor and a ligand. The higher the affinity between the targeted receptor and the radioligand, the more radioactive beam is released at the binding site to conduct clinical effects. Radioligand binding analysis service is an essential method to measure the interaction between receptors and different kinds of RDC, which provides crucial information and key properties for RDC development.
The binding analysis approaches have evolved for decades and include a wide range of highly sensitive binding assays. Rdcthera have top-notched platforms to characterize the affinity of your RDC product, as well as professional machine learning methods to calculate the affinity score of your RDC product with a mathematical model.
Rdcthera adhere strictly to our core technology and our scientists are all experienced and professional and undertake standard or custom analysis service on your samples according to your demand. Please contact us for more information.
Rdcthera offers efficient, customized, and professional R&D services related to radionuclide drug conjugates.